

REMARKS

In view of the above amendments, the single claim pending in the application is directed to applicant's novel paroxetine hydrochloride anhydrate Form B *per se*. Applicants note that paroxetine hydrochloride anhydrate Form B was allowed by the Examiner in the grandparent application - serial number 09/528,871. Because the subject application is directed to a novel polymorphic form of paroxetine that was previously allowed by the Examiner, applicants respectfully request the issuance of a notice of allowance.

Respectfully submitted,



Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

GLAXOSMITHKLINE
Corporate Intellectual Property-UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone: (610) 270-5023
Facsimile: (610) 270-5090
n:\wjd\paroxetine\p31178D7-C1preamend2.doc